| abstract |
A compositions and dosages forms that allow for high drug loading for highly lipophilic drugs while maintaining excellent oral bioavailability. The pharmaceutical compositions and unit dosage forms described herein can reduce pill burden for hydrophobic drugs like(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9, 11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl tridecanoate or (8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-l,2,6, 7,8,9,11,12,14,15,16,17- dodecahydrocyclopenta[a]phenanthren-17-yl tetradecanoate, and can be formulated at advantageous drug loads (e.g., greater than 23%) while providing suitable bioavailability (e.g., capable of treating a hypogonadal male with less than 10 unit dosage forms per day) that allows for reduction in pill burden and accordingly improved patient adherence or compliance. Additionally, the composition (e.g., dosage form) has a release profile that is suitable for providing bioavailable API and the release profile is stable over time (e.g., under storage conditions). |